...
首页> 外文期刊>Journal of paediatrics and child health >Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus.
【24h】

Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus.

机译:大剂量口服苯巴比妥口服液对难治性癫痫持续状态的抢救治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: Parenteral phenobarbitone was unavailable in South Africa from 2005 to 2006. This study aimed to establish the effectiveness of enteral phenobarbitone in the management of childhood status epilepticus. METHOD: Patients in status epilepticus (December 2005-June 2006) received 20 mg/kg phenobarbitone via nasogastric tube in addition to standard status interventions (benzodiazepine boluses, phenytoin infusion). Phenobarbitone concentrations were taken post loading. Phenobarbitone population pharmacokinetics was analysed using non-linear mixed effects modelling. RESULTS: Sixteen patients (7 female, 9 male) were assessed, median age 5 months (range 9 days-168 months). Nine patients received 20 mg/kg; the maximum total dosage administered was 80 mg/kg with a concentration of 283 micromol/L. The typical population value of the volume of distribution was 1.2 (95% confidence interval (CI): 0.8-1.6) L/kg with interindividual variability (as coefficient of variation) of 53% (95% CI, 9-74%). Seizure control was documented within 1 h (n= 8), 1(1)/(2) h (n= 1), 3 h (n= 1) and 4 h (n= 5) following enteral phenobarbitone loading. No adverse effects were apparent from the enteral phenobarbitone administration. CONCLUSION: Patients tolerated enteral loading with phenobarbitone. A single enteral loading dose resulted in adequate phenobarbitone exposure. This practice was a safe intervention for centres lacking parenteral phenobarbitone. Therapeutic concentrations and seizure control after enteral loading suggested a role for enteral phenobarbitone in the management of acute status epilepticus as well as prophylaxis against seizure recurrence.
机译:目的:从2005年至2006年,南非没有肠胃外苯巴比妥治疗。本研究旨在确定肠内苯巴比妥治疗儿童癫痫持续状态的有效性。方法:癫痫持续状态(2005年12月至2006年6月)的患者除标准状态干预措施(苯二氮卓类大剂量,苯妥英钠输注)外,还通过鼻胃管接受20 mg / kg苯巴比妥。苯巴比妥浓度是在加载后取得的。使用非线性混合效应模型分析了苯巴比妥人群的药代动力学。结果:评估了16例患者(7例女性,9例男性),中位年龄5个月(范围9天至168个月)。 9名患者接受了20 mg / kg的剂量;施用的最大总剂量为80 mg / kg,浓度为283 micromol / L。分布体积的典型总体值为1.2(95%置信区间(CI):0.8-1.6)L / kg,个体间变异性(作为变异系数)为53%(95%CI,9-74%)。记录苯巴比妥肠溶负荷后1 h(n = 8),1(1)/(2)h(n = 1),3 h(n = 1)和4 h(n = 5)内发作控制。肠内苯巴比妥治疗无明显不良反应。结论:苯巴比妥可耐受肠内负荷。单一肠内负荷剂量可导致苯巴比妥充分暴露。对于缺乏肠胃外苯巴比妥的中心来说,这种做法是一种安全的干预措施。肠内负荷后的治疗浓度和癫痫发作控制表明肠苯巴比妥酮在急性癫痫持续状态的管理以及预防癫痫发作的复发中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号